Corcept Therapeutics Incorporated

NasdaqCM:CORT 주식 보고서

시가총액: US$4.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Corcept Therapeutics 관리

관리 기준 확인 2/4

Corcept Therapeutics' CEO는 Joseph Belanoff, Jan1999 에 임명되었습니다 의 임기는 25.42 년입니다. 총 연간 보상은 $ 9.34M, 11.6% 로 구성됩니다. 11.6% 급여 및 88.4% 보너스(회사 주식 및 옵션 포함). 는 $ 79.72M 가치에 해당하는 회사 주식의 2.72% 직접 소유합니다. 79.72M. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 22.7 년입니다.

주요 정보

Joseph Belanoff

최고 경영자

US$9.3m

총 보상

CEO 급여 비율11.6%
CEO 임기25.7yrs
CEO 소유권2.9%
경영진 평균 재임 기간3.8yrs
이사회 평균 재임 기간22.9yrs

최근 관리 업데이트

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01
Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Corcept extends distribution agreement for Cushing’s syndrome drug

Sep 23

Corcept Therapeutics: A Status Check

Sep 06

Corcept cut to Hold at Truist on balanced risk-reward setup

Aug 01

CEO 보상 분석

Joseph Belanoff 의 보수는 Corcept Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

US$125m

Mar 31 2024n/an/a

US$117m

Dec 31 2023US$9mUS$1m

US$105m

Sep 30 2023n/an/a

US$91m

Jun 30 2023n/an/a

US$94m

Mar 31 2023n/an/a

US$94m

Dec 31 2022US$7mUS$896k

US$101m

Sep 30 2022n/an/a

US$117m

Jun 30 2022n/an/a

US$113m

Mar 31 2022n/an/a

US$112m

Dec 31 2021US$11mUS$844k

US$113m

Sep 30 2021n/an/a

US$106m

Jun 30 2021n/an/a

US$98m

Mar 31 2021n/an/a

US$99m

Dec 31 2020US$6mUS$770k

US$106m

Sep 30 2020n/an/a

US$109m

Jun 30 2020n/an/a

US$114m

Mar 31 2020n/an/a

US$106m

Dec 31 2019US$5mUS$708k

US$94m

Sep 30 2019n/an/a

US$87m

Jun 30 2019n/an/a

US$78m

Mar 31 2019n/an/a

US$76m

Dec 31 2018US$6mUS$680k

US$75m

Sep 30 2018n/an/a

US$152m

Jun 30 2018n/an/a

US$148m

Mar 31 2018n/an/a

US$142m

Dec 31 2017US$4mUS$647k

US$129m

보상 대 시장: Joseph 의 총 보상 ($USD 9.34M )은 US 시장( $USD 6.80M ).

보상과 수익: Joseph 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Joseph Belanoff (67 yo)

25.7yrs

테뉴어

US$9,337,734

보상

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...

리더십 팀

이름위치테뉴어보상소유권
Joseph Belanoff
Co-Founder25.7yrsUS$9.34m2.89%
$ 132.8m
Atabak Mokari
CFO & Treasurer3.5yrsUS$3.72m0.012%
$ 549.9k
Sean Maduck
President of Endocrinology8.4yrsUS$3.91m0.10%
$ 4.6m
William Guyer
Chief Development Officer3.1yrsUS$3.86m0.0056%
$ 254.8k
Gary Robb
Chief Business Officer & Secretary10.7yrsUS$3.96m0.040%
$ 1.8m
Joseph Lyon
Chief Accounting & Technology Officer4.2yrs데이터 없음0.0095%
$ 435.2k
Hazel Hunt
Chief Scientific Officer4.2yrsUS$3.11m0.11%
$ 5.2m
Amy Flood
Chief Human Resources & Communications Officer3.2yrs데이터 없음데이터 없음
Monica Tellado
President of Emerging Marketsless than a year데이터 없음데이터 없음
Roberto Vieira
President of Oncologyless than a year데이터 없음데이터 없음

3.8yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: CORT 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Joseph Belanoff
Co-Founder25.7yrsUS$9.34m2.89%
$ 132.8m
George Baker
Independent Director25.7yrsUS$492.53k5.08%
$ 233.3m
David Mahoney
Independent Director20.2yrsUS$509.03k1.26%
$ 57.7m
Charles Nemeroff
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
James Wilson
Independent Chairman25.7yrsUS$1.26m2.12%
$ 97.3m
Florian Holsboer
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Bruce McEwen
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Ned Kalin
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Edo Kloet
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Gregg Alton
Independent Director4.5yrsUS$511.53k0%
$ 0
K. Ranga Krishnan
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Kimberly Park
Independent Director5yrsUS$488.53k0%
$ 0

22.9yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 이사회: CORT 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 22.7 년).